Pasquale Amoia

Via Dei Vestini 31
Chieti, 66100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Synthesis, Biological Evaluation, and Computational Study of Pyridine- and Indazole-Based Inhibitors of the Inducible Nitric Oxide Synthase as Promising Antipsoriatic Agents.

Synthesis, Biological Evaluation, and Computational Study of Pyridine- and Indazole-Based Inhibitors of the Inducible Nitric Oxide Synthase as Promising Antipsoriatic Agents.

Journal: ACS pharmacology & translational science

Published: October 27, 2025

New amidine-benzenesulfonamides as iNOS inhibitors for the therapy of the triple negative breast cancer.

New amidine-benzenesulfonamides as iNOS inhibitors for the therapy of the triple negative breast cancer.

Journal: European journal of medicinal chemistry

Published: November 21, 2022

Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.

Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.

Journal: ACS medicinal chemistry letters

Published: May 27, 2020

Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.

Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.

Journal: MedChemComm

Published: May 20, 2019

Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.

Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.

Journal: European journal of medicinal chemistry

Published: March 14, 2019

The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.

The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.

Journal: International journal of molecular sciences

Published: December 20, 2018

Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.

Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.

Journal: MedChemComm

Published: May 28, 2018

Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.

Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.

Journal: European journal of medicinal chemistry

Published: December 13, 2017

Showing 1-8 of 8

Last Updated: 09/26/2026